Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grassberger

Showing results (151-160 of 231) with videos related to

Pageof 24
Sort By:
The Journal of Allergy and Clinical Immunology|August 10, 2001
The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophilsT Zuberbier, S U Chong, K Grunow, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancerClemens Grassberger, Stephen Dowdell, Antony Lomax, et al.
International Journal of Radiation Oncology, Biology, Physics|June 18, 2026
No evidence for depletion of circulating lymphocyte populations in primary brain tumor patients receiving radiotherapy aloneChris Beekman, Satoru Morita, Shane Neibart, et al.
Journal of Medicinal Chemistry|July 23, 1993
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatmentP Nussbaumer, G Dorfstätter, M A Grassberger, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
Synthesis of dammarane-type triterpenoids with anti-inflammatory activity in vivoDieter Scholz, Karl Baumann, Max Grassberger, et al.
Physics in Medicine and Biology|July 17, 2014
Computing proton dose to irregularly moving targetsJustin Phillips, Gueorgui Gueorguiev, James A Shackleford, et al.
Advances in Radiation Oncology|August 5, 2022
Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation TherapySusannah G Ellsworth, Anirudh Yalamanchali, Tim Lautenschlaeger, et al.
Medical Physics|May 3, 2013
Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributionsChuan Zeng, Drosoula Giantsoudi, Clemens Grassberger, et al.
Cancer Research|September 10, 2020
Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction PeriodDavid M McClatchy, Henning Willers, Aaron N Hata, et al.
International Journal of Radiation Oncology, Biology, Physics|July 5, 2023
Declarations of Independence: How Embedded Multicollinearity Errors Affect Dosimetric and Other Complex Analyses in Radiation OncologySusannah G Ellsworth, Peter S N van Rossum, Radhe Mohan, et al.
Pageof 24

Showing results (151-160 of 231) with videos related to

Sort By:
Pageof 24
The Journal of Allergy and Clinical Immunology|August 10, 2001
The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophilsT Zuberbier, S U Chong, K Grunow, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Motion interplay as a function of patient parameters and spot size in spot scanning proton therapy for lung cancerClemens Grassberger, Stephen Dowdell, Antony Lomax, et al.
International Journal of Radiation Oncology, Biology, Physics|June 18, 2026
No evidence for depletion of circulating lymphocyte populations in primary brain tumor patients receiving radiotherapy aloneChris Beekman, Satoru Morita, Shane Neibart, et al.
Journal of Medicinal Chemistry|July 23, 1993
Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatmentP Nussbaumer, G Dorfstätter, M A Grassberger, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
Synthesis of dammarane-type triterpenoids with anti-inflammatory activity in vivoDieter Scholz, Karl Baumann, Max Grassberger, et al.
Physics in Medicine and Biology|July 17, 2014
Computing proton dose to irregularly moving targetsJustin Phillips, Gueorgui Gueorguiev, James A Shackleford, et al.
Advances in Radiation Oncology|August 5, 2022
Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation TherapySusannah G Ellsworth, Anirudh Yalamanchali, Tim Lautenschlaeger, et al.
Medical Physics|May 3, 2013
Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributionsChuan Zeng, Drosoula Giantsoudi, Clemens Grassberger, et al.
Cancer Research|September 10, 2020
Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction PeriodDavid M McClatchy, Henning Willers, Aaron N Hata, et al.
International Journal of Radiation Oncology, Biology, Physics|July 5, 2023
Declarations of Independence: How Embedded Multicollinearity Errors Affect Dosimetric and Other Complex Analyses in Radiation OncologySusannah G Ellsworth, Peter S N van Rossum, Radhe Mohan, et al.
Pageof 24